Details of Disease

General Information of Disease (ID: DIS9U3YN)

• Disease Name: Cholangitis
• Synonyms: inflammation of biliary tree; biliary tree inflammation; biliary tract infection; cholangitis
• Definition: An acute or chronic inflammatory process affecting the biliary tract.
• Disease Hierarchy:
  DIS184KT: Skin inflammation
  DISWD40R: Disease
  DISUV4DU: Non-neoplastic bile duct disorder
  DIS9U3YN: Cholangitis
• Disease Identifiers:
  MONDO ID: MONDO_0004789
  MESH ID: D002761
  UMLS CUI: C0008311
  MedGen ID: 40258
  HPO ID: HP:0030151
  SNOMED CT ID: 82403002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amikacin	DM5PDRB	Approved	Small molecular drug	[1]
Ampicillin	DMHWE7P	Approved	Small molecular drug	[2]
Cefazolin	DMPDYFR	Approved	Small molecular drug	[3]
Erythromycin	DM4K7GQ	Approved	Small molecular drug	[4]
Fusidic Acid	DMWVCF3	Approved	Small molecular drug	[5]
Gentamicin	DMKINJO	Approved	Small molecular drug	[6]
Kanamycin	DM2DMPO	Approved	Small molecular drug	[7]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 8 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCB11	TTUXCAF	Limited	Altered Expression	[8]
CA2	TTANPDJ	moderate	Biomarker	[9]
CXCL2	TTZF0K2	moderate	Therapeutic	[10]
ABCB4	TTJUXV6	Strong	Biomarker	[11]
EGR1	TTE8LGD	Strong	Biomarker	[12]
ITGB6	TTKQSXZ	Strong	Biomarker	[12]
KRT19	TT3JF9E	Strong	Biomarker	[12]
TGFB2	TTI0KH6	Strong	Biomarker	[12]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC4A2	DTF7GAL	Definitive	Altered Expression	[13]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GPT	DER5HFI	Strong	Altered Expression	[14]

This Disease Is Related to 8 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
PLA2G2D	OTU604XM	Limited	Genetic Variation	[15]
COL1A1	OTI31178	Strong	Biomarker	[12]
EBAG9	OTTQLQCP	Strong	Biomarker	[16]
GGTLC1	OTWJKUHQ	Strong	Biomarker	[17]
OPN1MW	OTPJ7LX4	Strong	Biomarker	[18]
ORM2	OTRJGZP8	Strong	Altered Expression	[19]
PDZD2	OTPPVRGY	Strong	Biomarker	[20]
TIMP1	OTOXC51H	Strong	Biomarker	[12]

References

• [1] Amikacin FDA Label
• [2] Ampicillin FDA Label
• [3] Cefazolin FDA Label
• [4] Erythromycin FDA Label
• [5] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [6] Gentamicin FDA Label
• [7] Kanamycin FDA Label
• [8] Variations of ABCB4 and ABCB11 genes are associated with primary intrahepatic stones.Mol Med Rep. 2015 Jan;11(1):434-46. doi: 10.3892/mmr.2014.2645. Epub 2014 Oct 15.
• [9] Ursodeoxycholic acid (UDCA) suppresses liver interleukin 2 mRNA in the cholangitis model.Hepatogastroenterology. 2005 Mar-Apr;52(62):596-602.
• [10] Effect of glucocorticoid pretreatment on oxidative liver injury and survival in jaundiced rats with endotoxin cholangitis.World J Surg. 2006 Dec;30(12):2217-26. doi: 10.1007/s00268-006-0143-0.
• [11] ABCB4 missense mutations D243A, K435T, G535D, I490T, R545C, and S978P significantly impair the lipid floppase and likely predispose to secondary pathologies in the human population.Cell Mol Life Sci. 2017 Jul;74(13):2513-2524. doi: 10.1007/s00018-017-2472-6. Epub 2017 Feb 20.
• [12] Toxicogenomic analysis reveals profibrogenic effects of trichloroethylene in autoimmune-mediated cholangitis in mice.Toxicol Sci. 2014 Oct;141(2):515-23. doi: 10.1093/toxsci/kfu148. Epub 2014 Jul 23.
• [13] An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis.Lab Invest. 2018 Jun;98(6):745-754. doi: 10.1038/s41374-018-0045-4. Epub 2018 Mar 14.
• [14] Natural killer T cells mediate inflammation in the bile ducts.Mucosal Immunol. 2018 Nov;11(6):1582-1590. doi: 10.1038/s41385-018-0066-8. Epub 2018 Aug 16.
• [15] Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis.Hepatology. 1999 Apr;29(4):1026-36. doi: 10.1002/hep.510290440.
• [16] The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract.J Hepatol. 2002 Jun;36(6):786-92. doi: 10.1016/s0168-8278(02)00066-1.
• [17] Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.Invest New Drugs. 2017 Aug;35(4):529-536. doi: 10.1007/s10637-017-0453-0. Epub 2017 Mar 20.
• [18] Retrospective analysis of cases with an ectopic opening of the common bile duct into duodenal bulb.Adv Clin Exp Med. 2018 Oct;27(10):1361-1364. doi: 10.17219/acem/69691.
• [19] Plasma orosomucoid 2 as a potential risk marker of cholangiocarcinoma.Cancer Biomark. 2017;18(1):27-34. doi: 10.3233/CBM-160670.
• [20] Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis.Hepatology. 2007 Jun;45(6):1538-46. doi: 10.1002/hep.21697.